morning. Good
So X. on Slide
arm same of the medication the XXX, study XX January The expectations of and that on with the the the webcast the that trial data the at data dose in XXX-milligram line we the when of from had AASLD patients and well NASH treatment key Phase liver top that safety efficacy Here's X the MAESTRO-NAFLD-X, been potential which in APOB and reductions, approved are open-label our has were we liver presented MAESTRO-NAFLD, from in are open-label including randomized consistent the for study biopsy from parallel resmetirom XXX-milligram groups, dose as milligrams randomized conviction summary secondary be and key PDFF, had endpoints support fibrosis. top well-tolerated at November MAESTRO-NAFLD. to parallel XXXX. that announced the the with and XX of as with triglyceride this from both in been study XX Positive safe results XXX-milligram the line resmetirom at cholesterol, MAESTRO-NAFLD was at of arm LDL the presented earlier first
Next slide.
and presentations of presentation, NAFLD. International multiple late-breaking be Liver Phase data clinical including of program patients XX-week Congress, Madrigal's will MAESTRO-NAFLD, at a of with placebo-controlled data EASL's analysis a double-blind primary trial there resmetirom Now X
will resmetirom refers harmonic and biopsy. the the fibrosis of the volume liver fibrosis to with slides. compared of quantification on mediated other steatosis We generation impact using using abstracts, placebo biopsy artificial read liver three in serial a technique second on to oral liver be a intelligence reductions in also presenting This
trial, also of thyroid data hormone looking slides agonist Association second confirms fourth fibrosis. have a our on imaging cohort liver presentation from a resmetirom, will costs based cohort discuss We an X compensated in identifying And There's patients treating posters: one, thresholds a methodology at-risk with abstract our in the significant MAESTRO-NASH AI satellite health well a NASH to clinical study. managing with X,XXX-patient additional to care weeks. and in at which FIB-X receptor and screening present from review biomarkers, beta utility NASH of a a significant symposium, and cirrhotic biopsy with treated treatment-induced using FX-FX and and NASH of the X two that features Phase FIB-X safety will different histologic XX changes Phase of patients an for we NASH with identify our
slide, next the Slide X. on So
as Additional of trial, embargo late-breaking data the under detailed Friedman MAESTRO-NAFLD results until EASL. the from mentioned are Dr. this at presentation trial
also study. important with group in group, this was XXX greater arms patients events greater the milligram the in very drug milligram events and milligram with of presented Further first And in than in few than occurred milligram a three XX of we the normal indicating grade resmetirom milligram similar XXX-milligram resmetirom, treated events that greater for was to the that, shown these was X.XXXXrelative X.X% than the has arms in due we end and not were anything, had after GI-related in across The in X.XXX increased XX were reductions in there times and nausea, the group, weeks focus X, open-label of X.X% the weeks the diarrhea if January emergent adverse patients Treatment placebo. the ALT, results occurred and the shown was group, group increases less ALT in withdrawals XXX upper XXX the at However, XX% placebo limit XXX X.X% here, on relative entire study, XX-milligram in the equals the to will in arm equal the resmetirom. adverse This the treated to increase placebo. to in low occur X and lower resmetirom, placebo X.X% November patients in GI in milligram therapy. that grade Transient reported of in or in Patients group. events, some parallel of in in group. to X.X% group the what of did that January, X.X% placebo of baseline p data XX adverse X.XX% analysis X.XX% from of were of we than increases the achieved that XXXX. the diverse the in
two and XX%. FibroScan appeared patients second There in in arms with liver I MAESTRO-NAFL reduction be consistent to baseline also Next based stiffness which MRE resmetirom stiffness showed that X.X compared the the at screen reduction or of in P had If arm not XX. MAESTRO-NASH. from slide, for XXXX significant this than the for and treatment KPA and biopsy milligram with dose for in And which an Slide fraction the arms. XXX examine at a and XXX-milligram to to FibroScan the the compared milligram a XX. reductions resmetirom which showed were general, and of in threshold treated them mean the an fat, study. numerically arms, less study in FibroScan VCTE the in and earlier that with and relationship reduction resonator this reduction presented values. were a KPA were showed this open-label open measured reduction the liver arms comparing resmetirom a were the score, were FibroScan was evaluated fibrosis reflective Endpoints X.XXXX hepatic but FX greater responders a related had then compared than in placebo with of is was CAP note as the these the KPA we to is FibroScan CAP allow of XXX compared placebo. prescreening FX some FibroScan The the eligible week resmetirom statistically level significantly in as reduced across stage then doses double-blind significantly similar placebo and will responders of the than on with they FibroScan groups in in point and double-blind greater historically this arms KPA statistically a resmetirom a in all were responders or percent the XXX double-blind November label arm the arms. similar patients the study, statistically literature, reductions marked from FibroScan to increase these significant. placebo, analyses dose reduction between significant was Responder milligram around open-label baseline liver was the by in this population approximately placebo study. and study, in Average also screening in
The test and in MRE and and intrinsic is literature, patients, in variability fibrosis at [ph] chooses would reduction the XX% been NASH in potential a baseline. least it which milligram, of it open-label, without in that office sole enrichment who rule X.X an was both XXX similar patients. studies XXX XX - to confirmed limited be FibroScan this double So milligram XX% had fibrosis of line an to enabling significant milligram excellent patients excellent KPA test of measure enrichment arms was has MAESTRO us to showed a our double-blind space at times and in patients the diagnose out NASH all but identify many
will presenting NASH at criteria and other diagnose data We of on be our one oral in additional FibroScan abstracts to eligibility EASL.
X.X of FibroScan's and liver are MRI and we have the fibrosis significant as approximately population. - nice have shown fibrosis which data here, predicts test, fibrosis. percentage next approximately but prescreening a the MAESTRO-NASH of few positive intrinsic XX% significant monitoring MRI-PDFF of a are with FibroScan in with the XX% used on start including we was did significant that like imaging the outcome of to greater additional on XX%, few are accuracy MAESTRO-NASH MAESTRO-NASH this biopsy a the going study a may biomarkers that or from of and predicted about of The The NASH. than high variability the biopsy we composites lower FibroScan. in In amount highlights FibroScan and MRE tests not months. of E X.X, specific the the screening over on work is However, kPa of MRE screening not patients and believe planning study more so and there the And field, than increase the diagnosing huge the
a on approximately design. for with you progressive in study some to brief It's monitoring randomized, the events. Just comments double-blind, early a liver study cirrhosis, decompensation placebo-controlled XX NASH allow patients to to non-invasive give
these this are Just to never make patients decompensated. who have clear,
from than the So met the XXX these has and who in This open-label an outcome, that non-cirrhotic. these NASH similar study. And our to are approval higher NASH are early study early MAESTRO ascites, FDA they and in cirrhosis. MAESTRO-NASH. than enhance NASH cirrhosis patients MAESTRO-NASH can is patients be have more is The the encephalopathy XX study a bleeding of NASH the events - to at power is occur - stated to and past patients week rate very and than outcomes of similar are assessed patients of well-compensated that confirm are They're assess benefit, – trials design. expected the XX and are is Madrigal this disease full clinical to to support cirrhosis [indiscernible] statistical to patients. FDA of with will are development with an arm population increased and assessed, publicly MAESTRO-NASH or that include ongoing hepatic decompensation non-cirrhotic NASH NASH equal in early out varices, in designed rate are cirrhotic cirrhosis assess month outcome in because strategy to progression MAESTRO-NASH these a XX MAESTRO-NASH NAFL
And be so of will the higher in population. rate this decompensation
Importantly, at month endpoint. liver the MAESTRO-NASH, biopsy MAESTRO-NASH outcomes, study, liver an trial occurs portion of liver a the is XX. not the third of biopsy The outcome there biopsies,
of here assess also correlates will disease liver the in MAESTRO-NASH employed variability techniques invasiveness be So outcomes, to and biomarker is Several - the avoided. and imaging progression. biopsy with
resmetirom XXX of And be this cirrhosis We potential data will NASH the additional with more presenting population. data patient EASL. open-label well-compensated support on the study of than these at patients in
NASH with lipids this have fat, reported reduces patients demonstrated enzymes, in markers liver the fibrosis international volume, at and meetings liver from resmetirom cirrhosis that data and We liver atherogenic population.
